Tracer library / [177Lu]Lu-FAPI-2286
[177Lu]Lu-FAPI-2286
Also written as [Lu-177]Lu-FAPI-2286; Lu-177-FAPI-2286
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 2
What it is
- Compound class
- FAP-targeting peptide (DOTA-conjugated FAPI-2286)
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 41779297
- Clinical application
- FAP-targeted radioligand therapy in lung adenocarcinoma and sarcoma PMID 41432572
- Theranostic pair
- [64Cu]Cu-FAPI-2286
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | >95% | FAPI-2286 MedChemExpress | 41779297 2026 EJNMMI Res [177Lu]Lu-FAPI-2286 synthesis was performed using previously established protocols with minor modifications |
| Manual synthesis | — | SPE | — | — | DOTA-FAP-2286 | 41688618 2026 EJNMMI Res FAPI-46 and FAP-2286 were radiolabeled with 111In and 177Lu at a selected pH for 10 min at 100 °C, then purified with a SepPak cartridge |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- FAP-Targeted Theranostics in Advanced Sarcoma: A Pilot Study of ⁶⁸Ga-FAPI-46 Imaging and ¹⁷⁷Lu-FAPI-2286 Therapy.2026 · Clin Nucl Med · Prospective
- Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma.2024 · Eur J Nucl Med Mol Imaging · Prospective
- Superior Diagnostic Performance of ⁶⁸Ga-FAPI PET/CT Compared With ⁶⁸Ga-DOTATATE PET/CT in Medullary Thyroid Carcinoma.2026 · Clin Nucl Med · Clinical study
- Experience With 177 Lu-FAPI-2286 Therapy as the Last Resort in a Patient With Metastatic Colon Cancer.2026 · Clin Nucl Med · Clinical study
- FAP-targeted Radio-ligand Therapy in Pancreatic Neuroendocrine Tumor: A Potential Alternative to PRRT.2026 · Clin Nucl Med · Clinical study
- 177 Lu-FAPI-2286 Therapy in Metastatic Breast Cancer : A Case Study Highlighting the Potential Risk of Tumor Dedifferentiation and Hormonal Marker Elevation.2026 · Clin Nucl Med · Case report
- 177Lu-FAPI-2286 Therapy in a Patient With Radio-iodine Refractory Papillary Thyroid Carcinoma: A Favorable Clinical and Biochemical Response.2025 · Clin Nucl Med · Case report
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- MedChemExpress
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [177Lu]Lu-FAPI-2286, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 8 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Cu-64. Compound class inferred from precursor name (not stated outright) -- PMID 41779297: 'FAPI-2286 was purchased from MedChemExpress (Monmouth Junction, NJ, USA; catalog HY-147057)'. | Stage 28: added indication(s) onc-sarcoma from consolidated missing-rubric review.